one-centered, open, prospective, non-randomized, controlled clinical study will be aimed at creating remote monitoring system for patients' condition and the development of methodological approaches and its usage for conducting patients, who had myocardial infraction and who has a very high risk of developing an unfavorable outcome.

NCT04424368

Conditions

1. Myocardial Infarction
2. Adherence, Patient

Interventions

1. Device: The remote monitoring system

MeSH:Myocardial Infarction Infarction

HPO:Myocardial infarction

At the end of a 12 month observation with the registration of unfavorable cardiovascular occasions (death from cardiovascular reasons, nonfatal myocardial infraction, cerebral stroke, necessity for repeated revascularization of the coronary arteries) based on the analysis of non-genetic and genetic factors (polymorphism of genes Thr174Met and Met235Thr in gene angiotensinogen, Arg389Gly and Ser49Gly in gene adrenoceptor beta 1, Ser447Ter in gene lipoprotein lipase and Leu28Pro in gene apolipoprotein E, Trp212Ter and G681A in gene cytochrome P450 family 2 subfamily C member 19) factors of unfavorable prognosis will be identified and considering which group of patients requires the use of remote monitoring system will be formed. --- Thr174Met --- --- Met235Thr --- --- Arg389Gly --- --- Ser49Gly --- --- Leu28Pro --- --- G681A ---

This phase I trial is studying the side effects and best dose of stereotactic radiation therapy and nelfinavir mesylate when given together with gemcitabine hydrochloride, leucovorin calcium, and fluorouracil in treating patients with locally advanced pancreatic cancer. Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Drugs, such as nelfinavir mesylate, may make tumor cells more sensitive to radiation therapy. Drugs used in chemotherapy, such as gemcitabine hydrochloride, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving stereotactic radiation therapy and nelfinavir mesylate together with combination chemotherapy may kill more tumor cells.

NCT01068327

Conditions

1. Adenocarcinoma of the Pancreas
2. Stage III Pancreatic Cancer

Interventions

1. Drug: gemcitabine hydrochloride
2. Drug: leucovorin calcium
3. Drug: fluorouracil
4. Drug: nelfinavir mesylate
5. Radiation: stereotactic body radiation therapy
6. Radiation: hypofractionated radiation therapy
7. Procedure: therapeutic conventional surgery

MeSH:Pancreatic Neoplasms

HPO:Neoplasm of the pancreas

The pharmacokinetic parameters will be presented as the mean and standard deviation.. Pharmacogenomic status of CYP2C19*2 (G681A) (correlative). --- G681A ---

To measure the pharmacogenomic status of CYP2C19*2 (G681A) in the study population. --- G681A ---